Vishwanathan, KarthickSanchez-Simon, InmaculadaKeam, BhumsukPenel, Nicolasde Miguel-Luken, MariaWeilert, DorisMills, AndrewMarotti, MarceloJohnson, MartinRavaud, Alain2023-02-092023-02-092020http://hdl.handle.net/10668/15791Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. In this phase I study, we assessed the effects of normal renal function (NRF) and severe renal impairment (SRI) on the pharmacokinetics (PK) of osimertinib in patients with solid tumors. Part A: patients with NRF (creatinine clearance [CrCL] ≥90 mL/min), and SRI, (CrCLenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/epidermal growth factor receptorskidneynon-small cell lung cancerosimertinibpharmacokineticsrenal dispositiontyrosine kinase inhibitorsAcrylamidesAdministration, OralAgedAged, 80 and overAniline CompoundsAntineoplastic AgentsArea Under CurveFemaleHepatic InsufficiencyHumansKidney Function TestsMaleMiddle AgedNeoplasmsProtein Kinase InhibitorsSeverity of Illness Indexresearch article32567817open access10.1002/prp2.6132052-1707PMC7307240https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.613https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307240/pdf